Quantum BioPharma gets FDA clearance to advance Lucid-MS into Phase 2 progressive multiple sclerosis trial
Quantum BioPharma Ltd. (NASDAQ: QNTM) said on August 10, 2026 that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug programme for Lucid-MS, also known as Lucid-21-302, allowing the company to proceed with a randomized, double-blind, placebo-controlled Phase 2 study in progressive multiple sclerosis. The regulatory decision permits clinical development to